3 Beaten-Down Biotech Stocks to Buy Right Now
Biotech stocks that crater on negative clinical results or unfavorable regulatory developments can sometimes represent outstanding investing opportunities. Not all beaten-down biotech stocks, though, are diamonds in the rough.
Among the 15 biotech companies that saw their shares slide by more than 10% last month, for instance, I'd personally only consider buying shares of three: Intercept Pharmaceuticals (NASDAQ: ICPT), Exelixis (NASDAQ: EXEL), and Sage Therapeutics (NASDAQ: SAGE). Here's why.
Image Source: Getty Images.
Source: Fool.com
Exelixis Inc. Stock
€21.52
-0.050%
With 20 Buy predictions and not the single Sell prediction the community is currently very high on Exelixis Inc..
With a target price of 26 € there is a positive potential of 20.82% for Exelixis Inc. compared to the current price of 21.52 €.
